Bioventus (BVS) Financials: History & Chart

Bioventus Inc.(BVS)

Medical - Devices · Durham, NC

$13.10-0.42 (-3.11%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Durham, NC

950 employees

www.bioventus.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Robert Claypoole

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	581.85M	153.21M	132.09M	157.90M	138.65M	147.66M	123.88M	153.64M	138.96M
Cost of Goods Sold	186.20M	47.54M	42.43M	50.41M	45.82M	47.01M	42.41M	50.99M	45.41M
Gross Profit	395.64M	105.67M	89.66M	107.48M	92.83M	100.65M	81.46M	102.66M	93.55M
Gross Profit Margin	68.0%	69.0%	67.9%	68.1%	67.0%	68.2%	65.8%	66.8%	67.3%
Total Operating Expenses	333.81M	86.54M	80.77M	85.77M	80.73M	82.03M	76.49M	94.67M	89.48M
Research & Development	11.57M	3.17M	2.47M	3.01M	2.92M	3.17M	3.01M	3.25M	3.81M
Selling, General & Administrative	321.62M	82.74M	78.31M	82.77M	77.80M	78.86M	73.48M	86.61M	81.09M
Operating Income (EBIT)	61.83M	19.13M	8.89M	21.71M	12.10M	18.62M	4.97M	7.99M	4.07M
Operating Margin	10.6%	12.5%	6.7%	13.8%	8.7%	12.6%	4.0%	5.2%	2.9%
Income Before Tax (EBT)	38.64M	15.31M	4.52M	14.14M	4.67M	10.31M	-3.42M	232K	-4.83M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	19.88M	4.07M	4.33M	5.31M	6.18M	7.49M	7.51M	9.00M	9.53M
Other Income/Expense	-23.20M	-3.82M	-4.37M	-7.57M	-7.43M	-8.31M	-8.39M	-7.76M	-8.91M
Net Income	54.46M	33.44M	3.11M	14.76M	3.15M	7.46M	-2.64M	-156K	-4.82M
Income Tax Expense	-22.84M	-20.90M	571K	-3.17M	664K	1.04M	-95K	550K	589K
Net Profit Margin	9.4%	21.8%	2.4%	9.3%	2.3%	5.1%	-2.1%	-0.1%	-3.5%
EBITDA	107.08M	30.07M	20.09M	33.41M	23.51M	30.67M	16.84M	20.39M	16.35M
EBITDA Margin	18.4%	19.6%	15.2%	21.2%	17.0%	20.8%	13.6%	13.3%	11.8%
Depreciation & Amortization	45.25M	10.95M	11.21M	11.69M	11.40M	12.05M	11.87M	12.40M	12.28M
EPS Basic	0.80	0.49	0.05	0.22	0.05	0.11	-0.04	-0.00	-0.07
EPS Diluted	0.77	0.47	0.04	0.21	0.05	0.11	-0.04	-0.00	-0.07
Weighted Average Basic Shares	67.87M	67.87M	67.30M	66.62M	66.92M	66.50M	66.01M	65.45M	65.26M
Weighted Average Diluted Shares	70.84M	70.84M	70.01M	68.91M	68.84M	68.54M	66.01M	65.45M	65.26M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/06/2019	12/31/2018
Revenue	568.09M	573.28M	512.35M	512.12M	430.90M	321.16M	340.14M	319.18M
Cost of Goods Sold	185.66M	185.05M	184.15M	181.04M	128.19M	87.64M	90.94M	84.17M
Gross Profit	382.43M	388.23M	328.19M	331.08M	302.71M	233.52M	249.21M	235.01M
Gross Profit Margin	67.3%	67.7%	64.1%	64.6%	70.3%	72.7%	73.3%	73.6%
Total Operating Expenses	323.88M	400.20M	409.92M	498.31M	290.64M	212.28M	218.01M	209.50M
Research & Development	12.11M	13.64M	13.45M	23.85M	19.04M	11.20M	11.05M	8.10M
Selling, General & Administrative	311.77M	327.09M	303.88M	332.13M	254.25M	193.08M	198.47M	191.67M
Operating Income (EBIT)	58.55M	-11.98M	-81.72M	-167.23M	12.06M	21.24M	31.19M	25.50M
Operating Margin	10.3%	-2.1%	-16.0%	-32.7%	2.8%	6.6%	9.2%	8.0%
Income Before Tax (EBT)	25.71M	-49.13M	-121.11M	-189.03M	9.49M	15.91M	9.69M	6.11M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	26.49M	38.79M	40.68M	12.02M	1.11M	9.75M	21.58M	19.17M
Other Income/Expense	-32.84M	-37.15M	-39.39M	-21.79M	-2.57M	-5.32M	-21.50M	-19.40M
Net Income	22.73M	-33.54M	-156.23M	-158.70M	19.38M	16.41M	6.85M	-12.21M
Income Tax Expense	-1.56M	-5.29M	85K	-44.37M	-1.97M	1.19M	1.58M	1.66M
Net Profit Margin	4.0%	-5.9%	-30.5%	-31.0%	4.5%	5.1%	2.0%	-3.8%
EBITDA	105.56M	37.58M	-24.36M	-111.84M	46.94M	49.88M	61.51M	54.74M
EBITDA Margin	18.6%	6.6%	-4.8%	-21.8%	10.9%	15.5%	18.1%	17.2%
Depreciation & Amortization	47.01M	49.55M	57.37M	55.40M	34.88M	28.64M	30.32M	29.24M
EPS Basic	0.34	-0.52	-2.49	-2.59	0.43	0.44	0.12	-0.22
EPS Diluted	0.33	-0.52	-2.49	-2.59	0.43	0.44	0.12	-0.22
Weighted Average Basic Shares	66.62M	65.36M	62.65M	61.39M	45.47M	37.70M	56.83M	56.83M
Weighted Average Diluted Shares	68.91M	65.36M	62.65M	61.39M	45.47M	37.70M	56.83M	56.83M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.